top of page

BackTable / VI / Podcast / Episode #515

Curative Intent Therapies for HCC: Today & Tomorrow

with Dr. Kirema Garcia-Reyes, Dr. Kevin Burns, Dr. Sabeen Dhand and Dr. Zach Berman

"For hepatocellular carcinoma (HCC) patients who are not candidates for liver transplant or resection, lesion ablation can be a curative treatment. With multiple ablation options available and still under investigation, it can be challenging to navigate the differences between them. In this episode, Dr. Tyler Sandow hosts a discussion with interventional radiologists Dr. Kirema Garcia-Reyes, Dr. Sabeen Dhand, and Dr. Kevin Burns on the various ablation options for HCC and when to use each one.

Physicians, nurses, nurse practitioners, and physician assistants can follow this link to earn CME / CE credits for completing an accredited learning activity related to this discussion:
https://www.cmeuniversity.com/course/take/125738"

This podcast is supported by an educational grant from:

With additional support from:

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

Curative Intent Therapies for HCC: Today & Tomorrow with Dr. Kirema Garcia-Reyes, Dr. Kevin Burns, Dr. Sabeen Dhand and Dr. Zach Berman on the BackTable VI Podcast)
Ep 515 Curative Intent Therapies for HCC: Today & Tomorrow with Dr. Kirema Garcia-Reyes, Dr. Kevin Burns, Dr. Sabeen Dhand and Dr. Zach Berman
00:00 / 01:04

BackTable, LLC (Producer). (2025, February 7). Ep. 515 – Curative Intent Therapies for HCC: Today & Tomorrow [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Kirema Garcia-Reyes discusses Curative Intent Therapies for HCC: Today & Tomorrow on the BackTable 515 Podcast

Dr. Kirema Garcia-Reyes

Dr. Kirema Garcia-Reyes is an interventional radiologist and assistant professor with Mount Sinai in New York City.

Dr. Kevin Burns discusses Curative Intent Therapies for HCC: Today & Tomorrow on the BackTable 515 Podcast

Dr. Kevin Burns

Dr. Kevin Burns is the chief of interventional radiology at Mission Hospital in Mission Viejo, California.

Dr. Sabeen Dhand discusses Curative Intent Therapies for HCC: Today & Tomorrow on the BackTable 515 Podcast

Dr. Sabeen Dhand

Dr. Sabeen Dhand is a practicing interventional radiologist with PIH Health in Los Angeles.

Dr. Zach Berman discusses Curative Intent Therapies for HCC: Today & Tomorrow on the BackTable 515 Podcast

Dr. Zach Berman

Dr. Zachary Berman is an interventional radiologist at the University of California San Diego in San Diego, California.

Dr. Tyler Sandow discusses Curative Intent Therapies for HCC: Today & Tomorrow on the BackTable 515 Podcast

Dr. Tyler Sandow

Dr. Tyler Sandow is an interventional radiologist with Ochsner Health in New Orleans, Louisiana.

Synopsis

The doctors first discuss Barcelona-Clinic Liver Cancer (BCLC) Stage A patients, where lesion size and location are key factors in deciding between ablation and transarterial therapies. They then compare cryoablation and microwave ablation, highlighting that cryoablation offers better visualization and control of the ablation zone, while microwave ablation is more effective for treating larger lesions.

Dr. Burns introduces histotripsy, a noninvasive treatment that uses ultrasound energy to mechanically ablate tumors. He shares his experiences as an early adopter of this technology and discusses how intraoperative cone beam CT can help treat lesions located near critical structures or those poorly visualized on ultrasound. Finally, Dr. Garcia-Reyes and Dr. Berman provide insights into patient selection, pre-procedural imaging, and technical tips for Y90.

Timestamps

00:00 - Introduction
02:04 - Ablation vs Y90 in BCLC A Patients
05:58 - Same-Day Y90
15:55 - Y90 for Large Tumors
17:51 - Ideal Cases for Cryoablation
19:38 - Explanation of Histotripsy
32:09 - Procedural Specifics for Histotripsy
38:21 - Technical Tips for Y90

Resources

Including the Hollow Viscera (Stomach or Bowel) within the Ice Ball during Cryoablation: A Review of Adverse Events (Abramyan et al, 2024):
https://www.jvir.org/article/S1051-0443(24)00681-X/abstract

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

backtable-plus-vi-cta.jpg
Become a BackTable Sponsor

Up Next

Combination Therapy and Clinical Trials for Advanced HCC: What They Really Mean with Dr. Lingling Du, Dr. Jonathan Mizrahi, Dr. Adam Burgoyne and Dr. Zach Berman on the BackTable VI Podcast)
How to Simplify Dosing: Understanding Y90 Dosimetry from Simple to Complex with Dr. Tyler Sandow, Dr. Sabeen Dhand, Dr. Zach Berman, Dr. Kirema Garcia-Reyes and Dr. Sid Pdia on the BackTable VI Podcast)
Microwave Ablation Techniques: Dr. Ed Kim's Approach with Dr. Ed Kim on the BackTable VI Podcast)
Multidisciplinary Cancer Care: Lynn's Chemoembolization and More with Lynn Lazzaro on the BackTable VI Podcast)
Surviving Cancer: A Patient's Radioembolization Journey with Suzanne Martin on the BackTable VI Podcast)
Multidisciplinary HCC Care: Improving the Patient Experience with Combined Clinics with Dr. Tyler Sandow, Dr. Jonathan Mizrahi, Dr. Steven Young and Deondra Bonds-Adams on the BackTable VI Podcast)

Articles

Topics

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

Select which show(s) you would like to subscribe to:

Thanks! Message sent.

bottom of page